PHAROVENT
Timeline
27 events since 2013Board
Capital
Filings
Financial
Establishments
Other
2014201620182020202220242026
The 2026 accounts are due by 30-04-2027.
2026
Annual accounts 2025 filed PDFabbreviated format · 31 days before the deadline
2025
Back to profit net €52,983 The net result is €52,983, after one loss-making year.
Registered in the Peppol Directory Reachable for e-invoices through 0208:0536820170
Annual accounts 2024 filed PDFabbreviated format · 15 days before the deadline
2024
Annual accounts 2023 filed PDFabbreviated format · 1 day before the deadline
2023
(director) and (director) change roles“1. Assistentie op het gebied van management en het voeren van consultingactiviteiten. Het verlenen van…” (deed in Dutch) · 300 shares · General meeting of 21-12-20237 points ▸
- General meeting, 21-12-2023
- Purpose change, “1. Assistentie op het gebied van management en het voeren van consultingactiviteiten. Het verlenen van diensten,adviezen,de uitvoering,de studie en organisatie…” (deed in Dutch)
- 300 shares
- Director resignation, (manager)
- Director appointment, (director (not named in the articles))
- Director resignation, (manager)
- Director appointment, (director (not named in the articles))
- The deed holds 8 more points.
Back to profit net €104,523 The net result is €104,523, after one loss-making year.
Annual accounts 2022 filed PDFabbreviated format · 2 days before the deadline
2022
Weakest financial year net -€55,630 The net result drops to -€55,630, the lowest from 2014 to 2025. It recovers the following year.
Annual accounts 2021 filed PDFabbreviated format · 31 days before the deadline
2021
Annual accounts 2020 filed PDFabbreviated format · 32 days before the deadline
2020
Annual accounts 2019 filed PDFabbreviated format · 36 days before the deadline
2019
Annual accounts 2018 filed PDFabbreviated format · 32 days before the deadline
2018
Highest result from 2014 to 2025 net €137,721 ▲4.1% The operating result of €258,900 and the net result of €137,721 are both a record.
Equity above €500,000 equity €559,191 ▲32.7% With a profit in every financial year since 2014, equity grows to €559,191.
Annual accounts 2017 filed PDFabbreviated format · 38 days before the deadline
2017
Annual accounts 2016 filed PDFabbreviated format · 54 days before the deadline
2016
General meeting of 03-11-20161 point ▸
- General meeting, 03-11-2016
- The deed holds 3 more points.
Company renamed from TD PHARMA to PHAROVENT BVBA“Assistentie op het gebied van management en het voeren van consultingactiviteiten.Het verlenen van…” (deed in Dutch) · General meeting of 09-09-20163 points ▸
- Power of attorney,
- General meeting, 09-09-2016
- Name change, PHAROVENT BVBA
- The deed holds 3 more points.
Annual accounts 2015 filed PDFabbreviated format · 37 days before the deadline
appointed as managerGeneral meeting of 01-12-20152 points ▸
- General meeting, 01-12-2015
- Director appointment, (manager)
2015
Equity above €200,000 equity €216,127 ▲52.7% With a profit in every financial year since 2014, equity grows to €216,127.
Annual accounts 2014 filed PDFabbreviated format · 36 days before the deadline
2014
Merger: TD Pharma takes over Isem Pharma“Assistentie op het gebied van management en het voeren van consultingactiviteiten. Het verlenen van diensten…” (deed in Dutch) · The company holds all the shares of Isem Pharma · Share cancellation: Isem Pharma · General meeting of 30-06-20146 points ▸
- General meeting, 30-06-2014
- The company holds all the shares of Isem Pharma
- Share cancellation, Isem Pharma
- Capital, €100,000
- Capital, €100,000, 100 shares
- Director discharge, (manager)
- The deed holds 7 more points.
Merger proposal: BVBA TD PHARMA takes over BVBA ISEM PHARMAThe company holds all the shares of BVBA ISEM PHARMA4 points ▸
- The company holds all the shares of BVBA ISEM PHARMA
- Capital, €100,000, 100 shares
- Capital, €57,500, 100 shares
- Accounting effect, 01-01-2014
- The deed holds 5 more points.
2013
First establishment Strijpstraat 35, Kruisem
IncorporationFounding capital of €100,000, 100 shares · Founded by (comparant) · Capital of €100,000, 100 shares · published on 30-07-20133 points ▸
- Capital, €100,000, 100 shares
- Founder, (comparant)
- Founding capital, €100,000, 100 shares
- The deed holds 5 more points.
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
On 19 July 2013, PHAROVENT was incorporated by one private individual, with a starting capital of €100,000.12 Isem Pharma was merged into the company in 2014.3 The name was changed to PHAROVENT BVBA in 2016 and to PHAROVENT in 2016.45 Today the board has 2 members.6 Total assets went from €2.1m in 2019 to €2.8m in 2025.7